登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月27日，浙江海控南科华铁数智科技股份有限公司（以下简称"海南华铁（维权）"或"公司"） 发布公告称，公司和相关责任人收到浙江证监局下发的《行政处罚事先告知书》（浙处罚字[2025]25 号）。据处罚内容，海南华铁因存在重大合同临时公告披露不完整、重大合同进展披露不及时两项信息 披露违法违规行为，公司被责令改正、给予警告并合计罚款800万元，相关责任人员亦被罚款。上海市 信本律师事务所赵敬国律师（执业证号：13101200410820485）提示，于2025年3月5日-2025年9月30日 期间买入海南华铁股票，且在此期间有持仓记录，无论2025年10月1日及之后是否卖出的投资者，或可 通过"新浪股民维权平台"自愿登记索赔。（赵敬国律师专栏） 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首 ...

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to potential claims from affected investors [1][2][4] Group 1: Investigation Details - The CSRC issued a notice of investigation on December 26, 2025, regarding the company and its chairman for alleged information disclosure violations [1][3] - The Hainan Securities Regulatory Bureau identified issues in the company's sales practices in March 2025, including premature revenue recognition and abnormal sales prices, resulting in inaccurate financial data in periodic reports [4] - The company failed to timely disclose a profit warning for the negative net profit in 2024, only releasing the information in April 2025, which led to criticism from the Shanghai Stock Exchange [4] Group 2: Investor Compensation - Affected investors who purchased shares between August 29, 2024, and April 22, 2025, and still hold them, can voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [2][3] - The law firm involved has a history of successfully handling securities disputes and has represented investors in multiple compensation cases against various listed companies [3][4]

Core Viewpoint - ST HuLuWa Pharmaceutical Group Co., Ltd. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, impacting its operations and financial reporting [1] Group 1: Company Overview - ST HuLuWa, established in 2005, focuses on the research, production, and sales of pediatric medicines, with notable products including pediatric cough and asthma granules and intestinal inflammation capsules [1] - The company aims to establish itself as the "first brand of children's medicine in China" and was listed on the Shanghai Stock Exchange in July 2020 [1] Group 2: Financial Performance - From 2020 to 2024, ST HuLuWa reported stable annual revenues of over 1 billion yuan and approximately 100 million yuan in net profit [1] - However, in 2025, the company faced scrutiny for inaccurate financial disclosures, leading to a correction of its 2023 net profit to only 10.85 million yuan, a reduction of 89.81% from previously reported figures [2] - The 2024 financial report revealed a significant decline, with total revenue of 1.414 billion yuan, down 21.26% year-on-year, and a net loss of 274 million yuan, a staggering decrease of 2629.23% [2] Group 3: Regulatory Actions - Prior to the formal investigation, ST HuLuWa received disciplinary actions from the Shanghai Stock Exchange due to accounting errors and failure to timely disclose its 2024 earnings forecast [3] - The company and its executives faced public reprimands, which were recorded in the securities and futures market integrity database [3] Group 4: Current Operations - Despite the ongoing regulatory issues, ST HuLuWa reported that its production and operational activities continue to function normally [1] - The company's third-quarter report for 2025 indicated a revenue of approximately 683 million yuan, a year-on-year decline of 33.88%, with a loss of 11.21 million yuan [4] Group 5: Market Reaction - Following the announcement of the investigation, ST HuLuWa's stock experienced a significant drop, hitting the daily limit down for two consecutive days, with a current share price of 7.99 yuan and a total market capitalization of around 3.2 billion yuan [5]

Core Viewpoint - The company Beiqing Song faces regulatory scrutiny due to suspected information disclosure violations, leading to a significant drop in stock price and ongoing financial struggles [1][3]. Group 1: Company Overview - Beiqing Song, established in 2000, specializes in the design, research, development, production, sales, and service of smart portable health hardware, including various massage devices [1]. - The company went public on the Sci-Tech Innovation Board in July 2021 but has faced continuous financial pressure, reporting losses of 124 million yuan in 2022 and 50.87 million yuan in 2023, with a brief profit of 10.25 million yuan in 2024 [1]. Group 2: Financial Performance - In the first three quarters of the current year, Beiqing Song's performance deteriorated further, with both operating revenue and net profit attributable to shareholders declining year-on-year, resulting in losses exceeding 65 million yuan [1]. - The decline in revenue is attributed to a drop in online sales, while fixed expenses and rigid costs have not been adjusted accordingly [1]. Group 3: Marketing and R&D Issues - Beiqing Song has been criticized for prioritizing marketing over research and development, with advertising expenses consistently exceeding 50% of total sales costs [2]. - The company has a high sales personnel ratio of over 60%, significantly above the industry average of less than 24%, while the number of R&D staff has decreased, with only 11.86% of employees engaged in R&D as of mid-2025 [2]. Group 4: Quality and Service Complaints - The company's focus on light R&D has led to issues with product quality and after-sales service, resulting in numerous consumer complaints regarding product defects and poor service [2]. - Beiqing Song has faced legal challenges, including a lawsuit for patent infringement with a claim amount of 10 million yuan [2]. Group 5: Internal Governance and Financial Issues - Internal governance issues have been highlighted, with the company receiving regulatory inquiries regarding operational performance and allegations of irregular guarantees and fund misappropriation by the controlling shareholder, Ma Xuejun [3][4]. - Specific instances of fund misappropriation include loans from companies controlled by Ma Xuejun and early payments to suppliers that were redirected to his affiliates, totaling significant amounts from 2021 to 2024 [3]. Group 6: Regulatory Scrutiny and Responses - Beiqing Song has faced ongoing regulatory scrutiny, with the Shanghai Stock Exchange issuing inquiries about its financial management practices and internal controls [4][5]. - The company has acknowledged several irregularities and has taken corrective actions, including the disclosure of abnormal financial transactions and the sale of shares by Ma Xuejun, reducing his ownership stake [5].

12月29日ST葫芦娃公开信息显示，海南葫芦娃药业集团股份有限公司董事长刘景萍因涉嫌违反证券法 律法规、信息披露违规被中国证券监督管理委员会立案调查。 公司公告汇总 截至2025年12月29日收盘，ST葫芦娃(605199)报收于8.41元，下跌4.97%，换手率0.22%，成交量8884.0 手，成交额747.14万元。 当日关注点 交易信息汇总资金流向 12月29日主力资金净流出215.3万元，占总成交额28.82%；游资资金净流出59.12万元，占总成交额 7.91%；散户资金净流入274.42万元，占总成交额36.73%。 违规处罚提醒监管公告 海南葫芦娃药业集团股份有限公司及公司董事长刘景萍女士于2025年12月26日收到中国证券监督管理委 员会下发的《立案告知书》，因涉嫌信息披露违法违规，中国证监会决定对公司及刘景萍女士立案。公 司表示将积极配合调查，目前生产经营活动正常。公司指定信息披露媒体为《上海证券报》《中国证券 报》《证券日报》《证券时报》和上海证券交易所网站。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来 ...

Core Viewpoint - ST HuLuWa is facing severe challenges due to compliance issues and deteriorating performance, leading to regulatory scrutiny and significant financial losses [1][2][4] Group 1: Compliance and Regulatory Issues - ST HuLuWa has received a formal investigation notice from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company has previously been ordered to rectify financial discrepancies in its 2023 annual report, which included inaccurate revenue and profit disclosures [1] - The company’s internal controls have been deemed severely deficient, resulting in a negative opinion in the 2024 internal control audit report [2] Group 2: Financial Performance - In 2024, ST HuLuWa reported total revenue of 1.414 billion yuan, a year-on-year decline of 21.26%, and a net loss of 274 million yuan, a staggering drop of 2629.23% [2] - For the first half of 2025, the company’s revenue was 508 million yuan, down 42.89% from 889 million yuan in the same period of 2024, with a net profit of only 240,980 yuan, reflecting a 94.14% decline [3] - The core business segment, respiratory medications, saw revenue drop to 299 million yuan, accounting for 58.92% of total revenue, a decrease of 54.22% compared to the previous year [3] Group 3: Market and Operational Challenges - The company is experiencing a vicious cycle where compliance failures lead to a loss of market trust, further exacerbating operational difficulties [4] - Frequent errors in financial reporting and disclosure violations indicate serious deficiencies in internal governance, raising fundamental questions about the company's stability and management effectiveness [4]

*ST熊猫12月29日晚间公告，公司当日收到证监会下发的《立案告知书》，因公司涉嫌信息披露违法违 规，证监会决定对公司立案。 对于立案情况，*ST熊猫表示目前公司各项生产经营活动正常开展，在立案调查期间，公司将积极配合 证监会的调查工作，并严格按照相关法律法规及监管要求及时履行信息披露义务。 近八个交易日股价五次涨停，累计上涨超30%，*ST熊猫（600599）突然收到证监会《立案告知书》。 记者留意到，在今年7月*ST熊猫曾被湖南证监局出具警示函行政监管措施，原因系经查，*ST熊猫2024 年度业绩预告与2024 年年度报告披露的业绩存在较大差异，业绩预告与业绩更正公告均没有真实、完 整、准确地披露相关事项，信息披露不准确。 回溯案情，*ST熊猫在今年1月曾宣布2024 年度业绩预盈，预计实现净利润为3000万元到4500万元；不 过至4月28日，*ST熊猫披露更正公告称，预计 2024 年度实现净利润为亏损4.6亿元至4.8亿元，较业绩 预告由盈转亏。 值得注意的是，岁末将至，处于退市风险警示、其他风险警示中的*ST熊猫却突然进入了股价异动期， 12月18日至今的八个交易日，*ST熊猫完成了五次涨停，股价 ...

Core Viewpoint - GCL-Poly Energy Technology Co., Ltd. (referred to as "GCL-Poly") received a regulatory letter from the Shenzhen Stock Exchange regarding violations related to the use of raised funds and information disclosure [1][2] Group 1: Fund Usage Violations - GCL-Poly was found to have engaged in cash management beyond the board's approved timeframe for the use of raised funds. Specifically, the board approved a resolution on April 1, 2022, allowing the deposit of funds raised from a non-public stock issuance for a period not exceeding 12 months. However, the company failed to terminate the related deposit agreements in a timely manner, only doing so between May 8, 2023, and June 28, 2023 [1][2] Group 2: Information Disclosure Violations - The company disclosed inaccurate information in several reports, including the "2022 Semi-Annual Report on the Storage and Use of Raised Funds," the "2023 Annual Report on the Storage and Use of Raised Funds," and the "2024 Semi-Annual Report on the Storage and Use of Raised Funds" [1][2] Group 3: Accountability of Responsible Parties - The former financial directors, Sheng Yuxin and Peng Yi, along with the former board secretary, Shen Qiang, were held responsible for the violations. They failed to fulfill their duties and obligations as required by the Shenzhen Stock Exchange's regulations [2]

南财智讯12月29日电，ST人福公告，人福医药集团股份公司、武汉当代科技产业集团股份有限公司、 艾路明（时任当代集团董事）、李杰（时任人福医药董事长）、王学海（时任人福医药董事）、邓霞飞 （时任人福医药董事、总裁）、郑承刚（时任人福医药监事）、夏渊（时任人福医药职工监事）、吴亚 君（时任人福医药财务总监）、张红杰（时任人福医药副总裁）、李前伦（时任人福医药董事会秘书） 收到中国证券监督管理委员会湖北监管局的行政处罚决定书。经查明，人福医药未及时披露2021年至 2022年3月期间非经营性资金占用累计127.85亿元，2020年年度报告存在重大遗漏且虚假记载，虚增归 母净利润1.43亿元；2021年年度报告及2022年半年度报告存在虚假记载，分别虚增归母净利润0.72亿 元、0.91亿元；未及时披露与关联方珂美立德16.45亿元的物业资产交易，2022年年度报告存在重大遗 漏；控股股东当代集团隐瞒关联关系导致信息披露违规。对人福医药上述行为，责令给予警告，并合计 处以850.00万元罚款；对当代集团合计处以900.00万元罚款；对艾路明处以390.00万元罚款，并采取七 年证券市场禁入措施；对李杰给予警告，并处 ...

Core Viewpoint - The company Beiqing Song (倍轻松) is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, following the actual controller's recent cash-out of 64 million yuan, leading to a significant drop in stock price and ongoing financial struggles [3][4]. Group 1: Investigation and Regulatory Issues - Beiqing Song received a notice from the CSRC regarding the investigation into its actual controller, Ma Xuejun, for suspected information disclosure violations [3]. - The company has faced regulatory scrutiny for four consecutive years, receiving multiple inquiries from the exchange regarding its financial reports [4]. - Issues highlighted in the inquiries include operational business practices, sales expenses, customer and supplier relationships, inventory, and internal controls related to revenue recognition [5]. Group 2: Financial Mismanagement - The company disclosed instances of fund occupation and illegal guarantees in its 2024 annual report, with the internal control audit report issued with an emphasis paragraph by the accounting firm [5]. - Specific paths of fund occupation by Ma Xuejun and related parties include employee loans totaling 4.08 million yuan and 12.61 million yuan from 2023 to 2024, as well as transfers to Shenzhen Xingjiashun Trading Co., totaling 52 million yuan [6]. - The company has committed to improving internal management and controls in response to these issues, claiming that no new violations have occurred [6]. Group 3: Financial Performance and Shareholder Actions - Beiqing Song recorded a net loss of 124 million yuan in 2022 and continued to incur losses in 2023 and the first quarter of 2024, before achieving a profit of 10.25 million yuan in 2024 [7]. - The company reported a significant decline in online sales revenue in the first half of 2025, with decreases of 45.48%, 30.07%, and 44.18% across different online sales channels [8]. - Shareholders have been reducing their stakes, with significant sell-offs by the employee shareholding platform and the actual controller, Ma Xuejun, who sold shares worth approximately 64.71 million yuan [9].